We are live on ! Find out more
VYNE icon

VYNE Therapeutics
VYNE

106 hedge funds and large institutions have $160M invested in VYNE Therapeutics in 2020 Q2 according to their latest regulatory filings, with 35 funds opening new positions, 58 increasing their positions, 11 reducing their positions, and 22 closing their positions.

New
Increased
Maintained
Reduced
Closed

427% more repeat investments, than reductions

Existing positions increased: 58 | Existing positions reduced: 11

73% more capital invested

Capital invested by funds: $92.7M → $160M (+$67.5M)

59% more first-time investments, than exits

New positions opened: 35 | Existing positions closed: 22

14% more funds holding

Funds holding: 93 → 106 (+13)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

0.09% less ownership

Funds ownership: 0.79% → 0.7% (-0.09%)

Holders
106
Holders Change
+13
Holders Change %
+13.98%
% of All Funds
2.17%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.04%
New
35
Increased
58
Reduced
11
Closed
22
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
PA
Perceptive Advisors
New York
+$30.5M
2
Franklin Resources
Franklin Resources
California
+$12.7M
3
Vanguard Group
Vanguard Group
Pennsylvania
+$11.3M
4
BlackRock
BlackRock
New York
+$9.87M
5
6CM
683 Capital Management
New York
+$6.68M

Top Sellers

Rank Fund Capital Flow
1
GPP
Great Point Partners
Connecticut
-$4.43M
2
VP
venBio Partners
California
-$3.92M
3
MP
Mangrove Partners
Connecticut
-$2.83M
4
Point72 Asset Management
Point72 Asset Management
Connecticut
-$2.68M
5
O
OrbiMed
New York
-$2.18M
Name Holding Trade Value Shares
Change 		Change in
Stake
Nisa Investment Advisors
101
Nisa Investment Advisors
Missouri
$1K -$23.8K -176 -94%
CCM
102
Cribstone Capital Management
Maine
$1K +$406 +3 +100%
APWA
103
Atlas Private Wealth Advisors
New Jersey
$1K +$677 +5 New
GPP
104
Great Point Partners
Connecticut
– -$4.43M -22,945 Closed
VP
105
venBio Partners
California
– -$3.92M -20,299 Closed
MP
106
Mangrove Partners
Connecticut
– -$2.83M -14,641 Closed
Point72 Asset Management
107
Point72 Asset Management
Connecticut
– -$2.68M -13,889 Closed
BBA
108
Baker Bros. Advisors
New York
– -$1.68M -8,685 Closed
PHP
109
Parkman Healthcare Partners
Connecticut
– -$1.09M -5,644 Closed
SM
110
Senvest Management
New York
– -$756K -3,918 Closed
BCM
111
Bridgeway Capital Management
Texas
– -$283K -1,465 Closed
AIM
112
ARK Investment Management
Florida
– -$197K -1,018 Closed
Susquehanna International Group
113
Susquehanna International Group
Pennsylvania
– -$193K -1,003 Closed
IIA
114
IPG Investment Advisors
California
– -$97.6K -506 Closed
Acadian Asset Management
115
Acadian Asset Management
Massachusetts
– -$85K -441 Closed
PF
116
Phoenix Financial
Israel
– -$77K -406 Closed
DMK
117
David M. Knott
– -$66K -342 Closed
SCM
118
Sio Capital Management
New York
– -$61K -318 Closed
PP
119
PDT Partners
New York
– -$40K -210 Closed
Group One Trading
120
Group One Trading
Illinois
– -$37K -194 Closed
Stifel Financial
121
Stifel Financial
Missouri
– -$38K -189 Closed
Rockefeller Capital Management
122
Rockefeller Capital Management
New York
– -$21K -110 Closed
MAM
123
Meeder Asset Management
Ohio
– -$15K -75 Closed
ASN
124
Advisory Services Network
Georgia
– -$4K -18 Closed
EW
125
Evoke Wealth
California
– -$1.65K -9 Closed
2 3 4
5
6

VYNE Hedge Fund Activity: Q2 2020 in Review

106 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in VYNE Therapeutics (VYNE) for Q2 2020, worth a combined $160M — up 73% from $92.7M a quarter earlier.

Buyers outnumbered sellers: 35 funds opened new VYNE positions and 22 closed out — a net gain of 13 holders — while 58 added to existing stakes and 11 trimmed.

The largest buyer was Perceptive Advisors, adding an estimated $30.5M. The largest seller was Great Point Partners, exiting entirely with an estimated $4.43M sold.

  • 106 institutional investors held VYNE Therapeutics (VYNE) as of Q2 2020, up from 93 in Q1 2020.
  • Funds reported $160M of VYNE Therapeutics stock for Q2 2020, up 73% quarter-over-quarter.
  • 35 funds opened new VYNE Therapeutics positions in Q2 2020 and 22 closed out, a net change of +13 holders.
  • The largest VYNE Therapeutics buyer in Q2 2020 was Perceptive Advisors, an estimated $30.5M added.
  • The largest VYNE Therapeutics seller in Q2 2020 was Great Point Partners, an estimated $4.43M sold.

Based on aggregated 13F filings for Q2 2020.